GDF15 antagonism limits severe heart failure and prevents cardiac cachexia.

Heart failure and associated cachexia is an unresolved and important problem. This study aimed to determine the factors that contribute to cardiac cachexia in a new model of heart failure in mice that lack the integrated stress response (ISR) induced eIF2α phosphatase, PPP1R15A. Mice were irradiated...

Descripción completa

Detalles Bibliográficos
Autores: Takaoka, Minoru, Tadross, John A, Al-Hadithi, Ali B A K, Zhao, Xiaohui, Villena-Gutiérrez, Rocío, Tromp, Jasper, Absar, Shazia, Au, Marcus, Harrison, James, Coll, Anthony P, Marciniak, Stefan J, Rimmington, Debra, Oliver, Eduardo, Ibáñez, Borja, Voors, Adriaan A, O'Rahilly, Stephen, Mallat, Ziad, Goodall, Jane C
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/26541
Acceso en línea:https://hdl.handle.net/20.500.12105/26541
Access Level:acceso abierto
Palabra clave:Cachexia
GDF15
Heart failure
Integrated stress response
PPP1R15A
Descripción
Sumario:Heart failure and associated cachexia is an unresolved and important problem. This study aimed to determine the factors that contribute to cardiac cachexia in a new model of heart failure in mice that lack the integrated stress response (ISR) induced eIF2α phosphatase, PPP1R15A. Mice were irradiated and reconstituted with bone marrow cells. Mice lacking functional PPP1R15A, exhibited dilated cardiomyopathy and severe weight loss following irradiation, whilst wild-type mice were unaffected. This was associated with increased expression of Gdf15 in the heart and increased levels of GDF15 in circulation. We provide evidence that the blockade of GDF15 activity prevents cachexia and slows the progression of heart failure. We also show the relevance of GDF15 to lean mass and protein intake in patients with heart failure. Our data suggest that cardiac stress mediates a GDF15-dependent pathway that drives weight loss and worsens cardiac function. Blockade of GDF15 could constitute a novel therapeutic option to limit cardiac cachexia and improve clinical outcomes in patients with severe systolic heart failure.